{
    "relation": [
        [
            "Metric",
            "Relative Strength",
            "Overall Yield Attractiveness",
            "Dividend Reliability",
            "Dividend Uptrend",
            "Earnings Growth",
            "DARS Rating"
        ],
        [
            "AMGN Rank",
            "Sign Up For Ticker Ranking",
            "Sign Up For Ticker Ranking",
            "Sign Up For Ticker Ranking",
            "Sign Up For Ticker Ranking",
            "Sign Up For Ticker Ranking",
            "Sign Up For Ticker Ranking"
        ],
        [
            "AMGN Avg Ranking",
            "Sign Up For Sector Ranking",
            "Sign Up For Sector Ranking",
            "Sign Up For Sector Ranking",
            "Sign Up For Sector Ranking",
            "Sign Up For Sector Ranking",
            "Sign Up For Sector Ranking"
        ],
        [
            "Notes",
            "Stock is at the top of its six-month trading range.",
            "Stock's dividend yield is adequate.",
            "This rating is related to the length and consistency of a company's dividend payouts, as well as our opinion on how likely the company is to continue payouts in the future.",
            "Dividend payouts are consistent, but increases small.",
            "Earnings estimates are uptrending.",
            "Sign Up For DARS Ratings"
        ]
    ],
    "pageTitle": "AMGN: Dividend Date & History for Amgen - Dividend.com",
    "title": "",
    "url": "http://www.dividend.com/dividend-stocks/healthcare/biotechnology/amgn-amgen/",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 2,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989507.42/warc/CC-MAIN-20150728002309-00084-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 398581723,
    "recordOffset": 398557341,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{54000=\u00a9 2007-2015 Mitre Media II LLC. All rights reserved., 54867=Certain financial information included in Dividend.com is proprietary to Mergent, Inc. (\"Mergent\") Copyright \u00a9 2015. Reproduction of such information in any form is prohibited. Because of the possibility of human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the use of such information., 33021=Amgen (AMGN) - this company discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California., 54131=** Under no circumstances does the information on this website represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the 'publisher's exclusion' from the definition of 'investment adviser' as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.}",
    "textBeforeTable": "Get AMGN Ex-Dividend Alert Aug 13, 2015 Aug 13, 2015 Dividend Shot Clock\u00ae Amount $0.79 Date Aug 13 Next Ex-Dividend Date AMGN Upcoming Dividend Payouts Upcoming Dividend Payouts Get AMGN DARS\u2122 Rating DARS\u2122 Rating Since 2011 4 yrs Dividend Growth EPS $9.68 32.6% Payout Ratio Paid Quarterly $3.16 Annual Payout",
    "textAfterTable": "Get Email Updates Join over 100,000 investors who get the latest news from Dividend.com DARS Rating\u2122 Breakdown Dividend.com DARS Rating\u2122 Breakdown for AMGN Dividend.com Premium Sign Up to Unlock DARS\u2122 Ratings Sign Up Metric AMGN Rank AMGN Avg Ranking Notes Relative Strength Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock is at the top of its six-month trading range. Overall Yield Attractiveness Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock's dividend yield is adequate. Dividend Reliability Sign Up For Ticker Ranking Sign Up For",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}